Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Loteprednol etabonate ophthalmic preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
|
Loteprednol etabonate 5 mg/mL eye suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
|
Product containing precisely loteprednol etabonate 2 milligram/1 milliliter conventional release eye suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
|
Loteprednol etabonate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
|
Loteprednol etabonate + tobramycin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
|
Loteprednol etabonate 5 mg/mL and tobramycin 3 mg/mL eye suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
|
Product containing precisely loteprednol etabonate 2 milligram/1 milliliter conventional release eye suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely loteprednol etabonate 2 milligram/1 milliliter conventional release eye suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
1 |
Loteprednol etabonate 5 mg/mL eye suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
1 |
Loteprednol etabonate 5 mg/mL eye suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
1 |
Loteprednol etabonate 5 mg/mL and tobramycin 3 mg/mL eye suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
2 |
Loteprednol etabonate 5 mg/mL and tobramycin 3 mg/mL eye suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Loteprednol etabonate (substance) |
Inferred relationship |
Some |
2 |